← Back to Search

Monoclonal Antibodies

≥20 kg to <40 kg for COVID-19

Phase 2
Waitlist Available
Research Sponsored by Regeneron Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 weeks
Awards & highlights

Study Summary

This study is evaluating whether a drug called casirivimab can be safely given to people with cancer.

Eligible Conditions
  • COVID-19
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Concentrations of Casirivimab+Imdevimab in Serum Over Time.
Secondary outcome measures
Immunogenicity as Measured by NAb to Imdevimab Over Time
Immunogenicity as Measured by Neutralizing Antibodies (NAb) to Casirivimab Over Time
Number of Participants With Grade ≥3 Hypersensitivity Reactions
+5 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: ≥5 kg to <10 kgExperimental Treatment1 Intervention
SC administration
Group II: ≥3 kg to <5 kgExperimental Treatment1 Intervention
SC administration
Group III: ≥20 kg to <40 kgExperimental Treatment1 Intervention
SC administration
Group IV: ≥10 kg to <20 kgExperimental Treatment1 Intervention
SC administration
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
casirivimab+imdevimab
2021
Completed Phase 2
~300

Find a Location

Who is running the clinical trial?

Regeneron PharmaceuticalsLead Sponsor
615 Previous Clinical Trials
379,827 Total Patients Enrolled
13 Trials studying COVID-19
19,123 Patients Enrolled for COVID-19
Clinical Trial ManagementStudy DirectorRegeneron Pharmaceuticals
259 Previous Clinical Trials
251,037 Total Patients Enrolled
10 Trials studying COVID-19
18,863 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
2021. "COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04992273.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top